Cardiology Manuscripts & Trial Reporting: CONSORT 2025-Compliant Support for Cardiovascular Research

High-Impact Journals

Interesting topics

Cardiology Manuscripts & Trial Reporting: CONSORT 2025-Compliant Support for Cardiovascular Research

Modern cardiovascular research is becoming increasingly driven by complex randomised clinical trials, cutting-edge imaging techniques, digital health, artificial intelligence (AI), remote patient monitoring and clinical data. With increased technological sophistication of cardiovascular research, it becomes important that research papers report details regarding study design, execution, analysis and interpretation to make it comprehensible to researchers, clinicians, peer reviewers and patients alike. This makes cardiovascular research publication increasingly dependent on transparent and comprehensive reporting. [1]

The CONSORT 2025 statement represents the latest reporting guidelines for randomised clinical trials. It offers a 30-item checklist and participant flow diagram to promote clear, transparent and reproducible reporting of clinical trials. CONSORT 2025 is an updated version of the previously available CONSORT 2010 statement. Following the CONSORT 2025 checklist is an important step toward achieving CONSORT 2025 compliance.

For cardiology researchers, it is especially important to adhere to modern guidelines for clinical trial reporting since cardiovascular research uses increasingly many AI techniques, EHR, remote monitoring and medical imaging technology. [1]

1. Why CONSORT Reporting Matters in Cardiovascular Research

The randomised controlled trial is essential for assessing the safety and efficacy of cardiovascular interventions. Nevertheless, the scientific value of any well-planned trial can be compromised by poor reporting of its methodology and results. [2]

CONSORT reporting guidelines allow scientists to describe the trial in detail on:

trial methodology and subject selection
randomisation and intervention
outcome measurement and data analysis
subject flow and follow-up
harms and limitations
data sharing and open science

For cardiovascular manuscripts, such reporting is vital for the evaluation of its evidence validity and applicability. Proper randomised controlled trial reporting also strengthens the transparency of cardiology trial reporting.

2. CONSORT 2025: What Has Changed?

Key change	What CONSORT 2025 requires	Practical implication for authors
Data and code sharing	Report where and how de-identified participant-level data, the data dictionary, statistical code, and other relevant materials can be accessed.	Clearly state what data and code will be shared, where they are available, and any applicable access conditions.
Conflicts of interest	Report financial and other conflicts of interest for manuscript authors, in addition to funding and the role of funders.	Provide a transparent author-level conflict-of-interest statement and distinguish it from the funding statement.
Patient and public involvement	Report details of patient and/or public involvement in the design, conduct, and reporting of the trial.	State whether patients or members of the public were involved and describe their role, where applicable.
Harms assessment	Report how harms and other unintended effects were defined and assessed.	Explain how adverse events or other harms were identified and assessed, rather than only reporting the resulting events.
Analysis populations	Define who was included in each analysis and specify the group to which participants were assigned for analysis.	Explicitly identify the analysis population—for example, all randomized participants—and explain how participants were handled in each analysis.
Missing data	Report how missing data were handled in the analysis.	Describe the approach used for missing observations and, where relevant, explain assumptions or methods used to address missing data.
Actual intervention delivery	Report how the intervention and comparator were administered, including delivery, adherence, and fidelity where appropriate, as well as concomitant care.	Distinguish what was planned from what was delivered during the trial and report relevant deviations, adherence, and additional care.

CONSORT 2025 does not require researchers to follow a rigid manuscript structure. Instead, authors should address the relevant checklist items within the journal’s required format. This approach can support high-quality clinical trial manuscript writing and improve readiness for cardiovascular research publication.

3. Current Trends in Cardiovascular Clinical Trial Reporting

AI and Digital Technologies: AI is now being applied across many stages of the cardiovascular clinical trial process, ranging from patient selection, image evaluation, outcome measurement, trial design, analysis, to dissemination. However, this raises issues around accuracy, bias, privacy, and transparency. [3]

The recent studies in the field of cardiology have been investigating AI applications in the ECG, cardiac CT, echocardiography, disease diagnosis and screening, and optimizing procedures. The examples include the investigation of the use of AI in ECG for cardiovascular risk stratification and disease diagnosis, as well as the study of AI-based CT and echocardiography for improved imaging and clinical processes.

It is essential to report the details of the AI intervention, patient selection, comparison, outcomes, implementation, and analysis.

Remote Trials and Methods: Decentralized clinical trials increasingly use telemedicine, remote monitoring, wearable devices, and electronic data capture, which may improve accessibility and reduce participant burden. Trial reports should clearly describe remote outcome ascertainment, completeness of digital measurements, missing data, and follow-up procedures, because these factors can affect the validity and reliability of trial outcomes.

Open Science and Reproducibility: The current trend in reporting is based on transparency and reproducibility. The CONSORT 2025 Item 4 mandates that the authors report how the de-identified participant data (including data dictionary and statistical code), as well as any other material, can be accessed.

4. Reporting Cardiovascular AI Trials

Randomized trials involving AI as part of the intervention in the field of cardiology demand extra reporting issues. The CONSORT-AI guideline should be followed together with the basic CONSORT checklist for randomized trials that assess interventions that involve AI components. Authors need to report on the version of the algorithm, data input eligibility and processing, human-AI interaction, use of AI output to make clinical decisions, and performance error analysis.

The key aspects to report when writing an AI trial in cardiovascular diseases include:

The data source and study population;
The AI intervention and its intended use in clinical practice;
The comparator or the usual care approach;
The outcomes measured;
The model validation process;
The missing data strategy;
All possible biases and limitations, with Relevant potential sources of bias and study limitations
The involvement of humans in this procedure.

5. From Manuscript Preparation to Journal Submission

Compare the study documents against the protocol, statistical analysis plan, registry record, and reporting guidelines before you start writing. During the trial, ensure that there is proper documentation for protocol modifications, deviations, outcomes, and decisions made during the analysis process. When writing your manuscript, ensure that everything you document is consistent with the documentation you prepared during the trial. SPIRIT 2025 provides guidance on how to report a trial protocol while CONSORT 2025 is meant for reporting of randomized trials. [4]

Recommended Workflow for Reporting: Study protocol -> Trial conduct -> Data analysis -> CONSORT 2025 checklist -> Manuscript preparation -> Quality assurance -> Submission to journal.

This workflow supports clinical trial manuscript writing, CONSORT 2025 compliance, and successful cardiology journal submission while promoting transparent randomised controlled trial reporting.

6. Common Reporting Challenges in Cardiology Manuscripts

Cardiovascular researchers may encounter several reporting difficulties, particularly when trials involve complex interventions or emerging technologies.

Challenge	Cardiovascular example	Potential consequence
Composite endpoints	A primary endpoint combines cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure.	Individual components may have different clinical importance and treatment effects.
Follow-up periods	A trial reports outcomes at 30 days and 12 months after an intervention.	Different follow-up periods may produce different estimates of treatment effect.
Event ascertainment	Cardiovascular events are identified through hospital records, adjudication committees, or electronic health records.	Differences in ascertainment may affect outcome classification.
Time-to-event outcomes	Reporting only the percentage of patients experiencing myocardial infarction without accounting for follow-up time.	Time-to-event information and censoring may be obscured.
Treatment harms	Bleeding, vascular complications, or acute kidney injury following cardiovascular procedures.	Incomplete safety reporting may underestimate treatment risks.
AI-related reporting	An AI system assists in ECG interpretation or imaging-based diagnosis.	Readers may be unable to assess reproducibility or clinical applicability.

Addressing these challenges can improve cardiology trial reporting and strengthen the quality of manuscripts prepared for cardiology journal submission.

7. Supporting Transparent and Reproducible Cardiovascular Research

Cardiovascular trial reports should explain effect sizes, uncertainty, and clinical relevance alongside statistical significance. Researchers should describe how the results were obtained and analysed.

CONSORT 2025 stresses the need to compare the methods used in the trial with the original protocol. The authors must disclose any deviations in the protocol and give the reasons for them. This ensures transparency and prevents any changes to the protocol to conform to the results of the study.

In cardiovascular studies which use AI and digital technologies, it is even more important.

8. Role of Expert Manuscript and Trial Reporting Support

Manuscript assistance would help in ensuring that the cardiovascular research papers have been reported in accordance with the guidelines related to reporting. This would include the process of matching the content of the manuscripts with the guidelines, identifying inconsistencies for which clarification from the author would be needed, providing comments on reporting, methods, statistics, figures, tables, journals and pre-submission preparation. [5]

Expert support can help researchers review their manuscripts against the CONSORT 2025 checklist, strengthen clinical trial manuscript writing, and prepare manuscripts for cardiology journal submission.

Connect with us to explore how we can support you in maintaining academic integrity and enhancing the visibility of your research across the world!

Conclusion

CONSORT 2025 forms the basis of the reporting of randomised trials at present times, emphasising complete reporting, participant flow, reproducibility, and open science.

Hence, it becomes imperative that for cardiovascular manuscripts, the use of CONSORT 2025 should not merely be considered a manuscript submission requirement but rather a means to explain how the evidence has been gathered, analysed, and interpreted.

Request a cardiovascular manuscript reporting review with Pubrica’s CONSORT 2025 compliance assessment, manuscript review, and journal submission support. Prepare your cardiovascular research for publication with Pubrica.

Frequently Asked Questions (FAQs)

1. What is CONSORT 2025?

CONSORT 2025 is an updated reporting guideline for randomised clinical trials. It provides a 30-item checklist and participant flow diagram to support transparent, complete, and reproducible trial reporting.

2. Why is CONSORT 2025 important for cardiology research?

CONSORT 2025 helps cardiology researchers clearly report trial design, randomisation, outcomes, statistical analysis, participant flow, and harms, improving the transparency and reliability of cardiovascular research.

3. What should cardiovascular AI trials report?

Cardiovascular AI trials should clearly report the data source, study population, AI intervention, comparator, outcomes, validation process, missing-data strategy, potential biases, and human involvement.

4. Does CONSORT 2025 require a specific manuscript structure?

CONSORT 2025 does not require a rigid manuscript structure. Authors should address the relevant checklist items within the structure required by the target journal.

5. How can researchers improve CONSORT 2025 compliance?

Researchers can compare their manuscript with the CONSORT 2025 checklist, cross-check the study protocol and trial registration, verify statistical reporting, and ensure that participant flow, outcomes, harms, and data transparency are clearly reported.

References

Hopewell, S., Chan, A. W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., Bhandari, N., Butcher, N. J., Campbell, M. K., Chidebe, R. C. W., Elbourne, D., Farmer, A., Fergusson, D. A., Golub, R. M., Goodman, S. N., Hoffmann, T. C., … Boutron, I. (2025). CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ (Clinical research ed.), 389, e081123. https://doi.org/10.1136/bmj-2024-081123
Merkow, R. P., Kaji, A. H., & Itani, K. M. F. (2021). The CONSORT Framework. JAMA surgery, 156(9), 877–878. https://doi.org/10.1001/jamasurg.
Pater C. (2004). Current trends in the cardiovascular clinical trial arena (I). Current controlled trials in cardiovascular medicine, 5(1), 4. https://doi.org/10.1186/1468-6708-5-4
Ochner, C. N., & Mineo, J. (2020). A Brief Tutorial on Manuscript Preparation: From Journal Selection to Manuscript Review. HCA healthcare journal of medicine, 1(1), 3–10. https://doi.org/10.36518/2689-0216.1023
Smith PG, Morrow RH, Ross DA, editors. Field Trials of Health Interventions: A Toolbox. 3rd edition. Oxford (UK): OUP Oxford; 2015 Jun 1. Chapter 23, Reporting and using trial results. Available from: https://www.ncbi.nlm.nih.gov/books